ALMS Alumis Inc.

NASDAQ
$4.84

Alumis Inc. (ALMS) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.75 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -19.7% since its last earnings release on November 12, 2026.

Alumis Reported In-line with Estimates
Thursday, November 12, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($0.75)
Rev est $3.3M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.16

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Alumis Inc.

Alumis Inc. is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. The company's product candidate includes ESK-001. Alumis Inc. is based in SOUTH SAN FRANCISCO, Calif.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.